The market for preventive therapies to treat RSV Infections will experience modest annual growth over the 2010-2020 forecast period, as market size increase from $148.9 million to 777.49 million in European five countries, according to a new report from Research and Markets.
Respiratory syncytial virus (RSV) is a virus that causes infections of the lungs and respiratory tract. It’s so common that most children have been infected with the virus by their second year of life.
RSV can cause upper respiratory infections (such as cold, fever and otitis media) and lower respiratory tract infections (such as pneumonia, bronchiolitis, tracheobronchitis).
RSV also affects adults and can also become serious in older adult with heart and lung diseases, or anyone with a very weak immune system (immune compromised).
Filed Under: Drug Discovery